Sabarinath Venniyil Radhakrishnan

Title: Sabarinath Venniyil Radhakrishnan: Innovator in CAR T Cell Technology

Introduction

Sabarinath Venniyil Radhakrishnan is a notable inventor based in Salt Lake City, UT (US). He has made significant contributions to the field of immunotherapy, particularly through his work on chimeric antigen receptor (CAR) T cells. His innovative approach has the potential to transform cancer treatment.

Latest Patents

Radhakrishnan holds a patent for "CD229 CAR T cells and methods of use thereof." This patent discloses chimeric antigen receptor (CAR) polypeptides that include a CD229 antigen binding domain, a transmembrane domain, and an intracellular signaling domain. The patent also covers nucleic acid sequences capable of encoding these CAR polypeptides, as well as vectors and cells that incorporate them. The methods outlined in the patent aim to enhance treatment options for patients.

Career Highlights

Radhakrishnan is affiliated with the University of Utah Research Foundation, where he continues to advance his research in CAR T cell technology. His work is pivotal in the ongoing development of innovative therapies for cancer treatment.

Collaborations

He collaborates with esteemed colleagues such as Tim Luetkens and Djordje Atanackovic, contributing to a dynamic research environment focused on cutting-edge medical advancements.

Conclusion

Sabarinath Venniyil Radhakrishnan is a key figure in the field of CAR T cell technology, with a patent that showcases his innovative contributions. His work at the University of Utah Research Foundation and collaborations with other experts highlight his commitment to advancing cancer treatment.